Pharvaris N.V.PHVSNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank50
5Y CAGR-47.1%
Year-over-Year Change
Year-over-year research & development expense growth
5Y CAGR
-47.1%/yr
Long-term compound
Percentile
P50
Within normal range
vs 5Y Ago
0x
Contraction
Streak
2 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q3 2025 | 0.70% |
| Q2 2025 | -4.23% |
| Q1 2025 | -7.11% |
| Q4 2024 | 29.08% |
| Q3 2024 | 11.77% |
| Q2 2024 | 24.60% |
| Q1 2024 | -7.51% |
| Q4 2023 | 7.99% |
| Q3 2023 | 16.00% |
| Q2 2023 | 8.35% |
| Q1 2023 | -9.93% |
| Q4 2022 | 15.43% |
| Q3 2022 | -2.87% |
| Q2 2022 | 8.06% |
| Q1 2022 | 26.29% |
| Q4 2021 | 19.48% |
| Q3 2021 | 11.11% |
| Q2 2021 | -0.13% |
| Q2 2021 | 4.69% |
| Q4 2020 | 52.29% |
| Q3 2020 | 16.87% |
| Q2 2020 | 80.24% |
| Q1 2020 | -14.19% |
| Q4 2019 | 97.08% |
| Q3 2019 | 0.00% |
| Q2 2019 | 0.00% |
| Q1 2019 | 55.94% |
| Q4 2018 | 0.00% |
| Q3 2018 | 0.00% |
| Q2 2018 | 0.00% |
| Q1 2018 | 0.00% |
| Q4 2017 | 0.00% |
| Q3 2017 | 0.00% |
| Q2 2017 | 0.00% |
| Q1 2017 | 0.00% |